Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 8/2023

10.06.2023 | Lipid Abnormalities and Cardiovascular Prevention (ED Michos, Section Editor)

Supplements for Lipid Lowering: What Does the Evidence Show?

verfasst von: Saeid Mirzai, Luke J. Laffin

Erschienen in: Current Cardiology Reports | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

In this review, the regulation, proposed hypolipidemic mechanism, and efficacy of common dietary supplements (DSs) marketed for cardiovascular health are discussed.

Recent Findings

Data demonstrate modest but inconsistent lipid-lowering effects with common DSs such as probiotics, soluble fibers, plant sterols, green tea, berberine, guggul, niacin, and garlic. Furthermore, data is limited regarding turmeric, hawthorn, and cinnamon. Red yeast rice has shown to be a beneficial DS, but its safety and efficacy are dependent upon its production quality and monacolin K content, respectively. Finally, soy proteins and omega-3 fatty acid-rich foods can have significant health benefits if used to displace other animal products as part of a healthier diet.

Summary

Despite the rising use of DSs, data demonstrate unpredictable results. Patients should be educated on the difference between these DSs and evidence-based lipid-lowering medications proven to improve cardiovascular outcomes.
Literatur
1.
Pirillo A, Casula M, Olmastroni E, Norata GD, Catapano AL. Global epidemiology of dyslipidaemias. Nat Rev Cardiol. 2021;18:689–700.PubMedCrossRef
2.
Wall HK, Ritchey MD, Gillespie C, Omura JD, Jamal A, George MG. Vital Signs: Prevalence of Key Cardiovascular Disease Risk Factors for Million Hearts 2022 — United States, 2011–2016. MMWR Morb Mortal Wkly Rep. 2018;67:983–91.PubMedPubMedCentralCrossRef
3.
Cowan AE, Tooze JA, Gahche JJ, Eicher-Miller HA, Guenther PM, Dwyer JT, Potischman N, Bhadra A, Carroll RJ, Bailey RL. Trends in Overall and Micronutrient-Containing Dietary Supplement Use in US Adults and Children, NHANES 2007–2018. J Nutr. 2022;152:2789–801.PubMedCentralCrossRef
4.
Hunter PM, Hegele RA. Functional foods and dietary supplements for the management of dyslipidaemia. Nat Rev Endocrinol. 2017;13:278–88.PubMedCrossRef
5.
Huang J, Frohlich J, Ignaszewski AP. The impact of dietary changes and dietary supplements on lipid profile. Can J Cardiol. 2011;27:488–505.PubMedCrossRef
6.
•• Bailey RL. Current regulatory guidelines and resources to support research of dietary supplements in the United States. Crit Rev Food Sci Nutr. 2020;60:298–309. Comprehensive review of the current regulatory framework for dietary supplements in the United States.PubMedCrossRef
7.
Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64:485–94.PubMedPubMedCentralCrossRef
8.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143.PubMed
9.
Nissen SE. The US Food and Drug Administration: a dysfunctional agency in need of major reforms. Curr Cardiol Rep. 2007;9:167–9.PubMedCrossRef
10.
11.
12.
Wallace TC. Twenty years of the dietary supplement health and education act—how should dietary supplements be regulated? J Nutr. 2015;145:1683–6.PubMedCrossRef
13.
Thomas PR, Coates PM, Haggans CJ. Chapter 35 - Dietary supplements. In: Marriott BP, Birt DF, Stallings VA, Yates AA, editors. Present Knowledge in Nutrition (Eleventh Edition). Academic Press; 2020. p. 573–90.CrossRef
14.
15.
16.
Jia B, Zou Y, Han X, Bae J-W, Jeon CO. Gut microbiome-mediated mechanisms for reducing cholesterol levels: implications for ameliorating cardiovascular disease. Trends Microbiol. 2023;31:76–91.PubMedCrossRef
17.
Ghorbani Z, Kazemi A, UP Bartolomaeus T, Martami F, Noormohammadi M, Salari A, et al. The effect of probiotic and synbiotic supplementation on lipid parameters among patients with cardiometabolic risk factors: a systematic review and meta-analysis of clinical trials. Cardiovasc Res. 2022:cvac128.
18.
19.
Cho YA, Kim J. Effect of probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2015;94:e1714.PubMedCrossRef
20.
Guo Z, Liu XM, Zhang QX, Shen Z, Tian FW, Zhang H, et al. Influence of consumption of probiotics on the plasma lipid profile: a meta-analysis of randomised controlled trials. Nutr Metab Cardiovasc Dis. 2011;21:844–50.PubMedCrossRef
21.
Sun J, Buys N. Effects of probiotics consumption on lowering lipids and CVD risk factors: a systematic review and meta-analysis of randomized controlled trials. Ann Med. 2015;47:430–40.PubMedCrossRef
22.
Zarezadeh M, Musazadeh V, Faghfouri AH, Roshanravan N, Dehghan P. Probiotics act as a potent intervention in improving lipid profile: an umbrella systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2023;63:145–58.PubMedCrossRef
23.
24.
Nijjar PS, Burke FM, Bloesch A, Rader DJ. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol. 2010;4:248–58.PubMedCrossRef
25.
26.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–88.PubMedCrossRef
27.
Fu L, Zhang G, Qian S, Zhang Q, Tan M. Associations between dietary fiber intake and cardiovascular risk factors: An umbrella review of meta-analyses of randomized controlled trials. Front Nutr. 2022;9.
28.
Mattson FH, Volpenhein RA, Erickson BA. Effect of plant sterol esters on the absorption of dietary cholesterol. J Nutr. 1977;107:1139–46.PubMedCrossRef
29.
Demonty I, Ras RT, van der Knaap HCM, Duchateau GSMJE, Meijer L, Zock PL, et al. Continuous dose-response relationship of the LDL-cholesterol–lowering effect of phytosterol intake 1,2. J Nutr. 2009;139:271–84.PubMedCrossRef
30.
Musa-Veloso K, Poon TH, Elliot JA, Chung C. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2011;85:9–28.PubMedCrossRef
31.
Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr. 2014;112:214–9.PubMedPubMedCentralCrossRef
32.
33.
Han S, Jiao J, Xu J, Zimmermann D, Actis-Goretta L, Guan L, et al. Effects of plant stanol or sterol-enriched diets on lipid profiles in patients treated with statins: systematic review and meta-analysis. Sci Rep. 2016;6:31337.PubMedPubMedCentralCrossRef
34.
Koo SI, Noh SK. Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect. J Nutr Biochem. 2007;18:179–83.PubMedPubMedCentralCrossRef
35.
Zheng X-X, Xu Y-L, Li S-H, Liu X-X, Hui R, Huang X-H. Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials. Am J Clin Nutr. 2011;94:601–10.PubMedCrossRef
36.
Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24:823–36.PubMedCrossRef
37.
Xu R, Yang K, Li S, Dai M, Chen G. Effect of green tea consumption on blood lipids: a systematic review and meta-analysis of randomized controlled trials. Nutr J. 2020;19:1–15.CrossRef
38.
Zamani M, Kelishadi MR, Ashtary-Larky D, Amirani N, Goudarzi K, Torki IA, et al. The effects of green tea supplementation on cardiovascular risk factors: a systematic review and meta-analysis. Front Nutr. 2023;9:1084455.PubMedPubMedCentralCrossRef
39.
Wang Z-M, Zhou B, Wang Y-S, Gong Q-Y, Wang Q-M, Yan J-J, et al. Black and green tea consumption and the risk of coronary artery disease: a meta-analysis. Am J Clin Nutr. 2011;93:506–15.PubMedCrossRef
40.
Tang J, Zheng J-S, Fang L, Jin Y, Cai W, Li D. Tea consumption and mortality of all cancers, CVD and all causes: a meta-analysis of eighteen prospective cohort studies. Br J Nutr. 2015;114:673–83.PubMedCrossRef
41.
Zou J, Zhang S, Li P, Zheng X, Feng D. Supplementation with curcumin inhibits intestinal cholesterol absorption and prevents atherosclerosis in high-fat diet–fed apolipoprotein E knockout mice. Nutr Res. 2018;56:32–40.PubMedCrossRef
42.
Yuan F, Dong H, Gong J, et al. A systematic review and meta-analysis of randomized controlled trials on the effects of turmeric and curcuminoids on blood lipids in adults with metabolic diseases. Adv Nutr. 2019;10:791–802.PubMedPubMedCentralCrossRef
43.
Simental-Mendía LE, Pirro M, Gotto AM, Banach M, Atkin SL, Majeed M, et al. Lipid-modifying activity of curcuminoids: a systematic review and meta-analysis of randomized controlled trials. Crit Rev Food Sci Nutr. 2019;59:1178–87.PubMedCrossRef
44.
Saeedi F, Farkhondeh T, Roshanravan B, Amirabadizadeh A, Ashrafizadeh M, Samarghandian S. Curcumin and blood lipid levels: an updated systematic review and meta-analysis of randomised clinical trials. Arch Physiol Biochem. 2022;128:1493–502.PubMedCrossRef
45.
Mirzaei H, Shakeri A, Rashidi B, Jalili A, Banikazemi Z, Sahebkar A. Phytosomal curcumin: a review of pharmacokinetic, experimental and clinical studies. Biomed Pharmacother. 2017;85:102–12.PubMedCrossRef
46.
Sacks FM, Lichtenstein A, Van Horn L, Harris W, Kris-Etherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee. Circulation. 2006;113:1034–44.PubMedCrossRef
47.
Mullen E, Brown RM, Osborne TF, Shay NF. Soy isoflavones affect sterol regulatory element binding proteins (SREBPs) and SREBP-regulated genes in HepG2 cells. J Nutr. 2004;134:2942–7.PubMedCrossRef
48.
49.
Jenkins DJA, Blanco Mejia S, Chiavaroli L, Viguiliouk E, Li SS, Kendall CWC, et al. Cumulative meta-analysis of the soy effect over time. J Am Heart Assoc. 2019;8:e012458.PubMedPubMedCentralCrossRef
50.
Blanco Mejia S, Messina M, Li SS, et al. A meta-analysis of 46 studies identified by the FDA demonstrates that soy protein decreases circulating LDL and total cholesterol concentrations in adults. J Nutr. 2019;149:968–81.PubMedPubMedCentralCrossRef
51.
Jenkins DJA, Mirrahimi A, Srichaikul K, Berryman CE, Wang L, Carleton A, et al. Soy protein reduces serum cholesterol by both intrinsic and food displacement mechanisms. J Nutr. 2010;140:2302S–2311S.PubMedCrossRef
52.
Wang Y, Zidichouski JA. Update on the benefits and mechanisms of action of the bioactive vegetal alkaloid berberine on lipid metabolism and homeostasis. Cholesterol. 2018;2018:e7173920.CrossRef
53.
Zamani M, Zarei M, Nikbaf-Shandiz M, Hosseini S, Shiraseb F, Asbaghi O. The effects of berberine supplementation on cardiovascular risk factors in adults: a systematic review and dose-response meta-analysis. Front Nutr. 2022;9.
54.
Cicero A, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. Clin Lipidol. 2009;4:553–63.CrossRef
55.
Szapary PO, Wolfe ML, Bloedon LT, Cucchiara AJ, DerMarderosian AH, Cirigliano MD, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA. 2003;290:765–72.PubMedCrossRef
56.
Agarwal RC, Singh SP, Saran RK, Das SK, Sinha N, Asthana OP, et al. Clinical trial of gugulipid–a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res. 1986;84:626–34.PubMed
57.
Gopal K, Saran RK, Nityanand S, Gupta PP, Hasan M, Das SK, et al. Clinical trial of ethyl acetate extract of gum gugulu (gugulipid) in primary hyperlipidemia. J Assoc Physicians India. 1986;34:249–51.PubMed
58.
Nityanand S, Srivastava J, Asthana O. Clinical trials with gugulipid: a new hypolipidaemic agent. J Assoc Physicians India. 1989;37:323–8.PubMed
59.
Koch E, Malek FA. Standardized extracts from hawthorn leaves and flowers in the treatment of cardiovascular disorders – preclinical and clinical studies. Planta Med. 2011;77:1123–8.PubMedCrossRef
60.
Wu M, Liu L, Xing Y, Yang S, Li H, Cao Y. Roles and mechanisms of hawthorn and its extracts on atherosclerosis: a review. Front Pharmacol. 2020;11.
61.
Dalli E, Colomer E, Tormos MC, Cosín-Sales J, Milara J, Esteban E, et al. Crataegus laevigata decreases neutrophil elastase and has hypolipidemic effect: A randomized, double-blind, placebo-controlled trial. Phytomedicine. 2011;18:769–75.PubMedCrossRef
62.
Hu M, Zeng W, Tomlinson B. Evaluation of a crataegus-based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial. Evid Based Complement Alternat Med. 2014;2014:e365742.CrossRef
63.
Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol. 2006;98:27–33.CrossRef
64.
65.
Nicholls SJ, Lincoff AM, Garcia M, et al. effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324:2268–80.PubMedPubMedCentralCrossRef
66.
Rimm EB, Appel LJ, Chiuve SE, Djoussé L, Engler MB, Kris-Etherton PM, et al. Seafood long-chain n-3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2018;138:e35–47.PubMedPubMedCentralCrossRef
67.
Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140:e673–91.PubMedCrossRef
68.
Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J Nutr Biochem. 2003;14:298–305.PubMedCrossRef
69.
Schandelmaier S, Briel M, Saccilotto R, Olu KK, Arpagaus A, Hemkens LG, et al. Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev. 2017;2017:CD009744.PubMedCentral
70.
Garg A, Sharma A, Krishnamoorthy P, Garg J, Virmani D, Sharma T, et al. Role of niacin in current clinical practice: a systematic review. Am J Med. 2017;130:173–87.PubMedCrossRef
71.
Investigators AIM-HIGH, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67.CrossRef
72.
HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12.CrossRef
73.
Mollazadeh H, Hosseinzadeh H. Cinnamon effects on metabolic syndrome: a review based on its mechanisms. Iran J Basic Med Sci. 2016;19:1258–70.PubMedPubMedCentral
74.
Maierean SM, Serban M-C, Sahebkar A, Ursoniu S, Serban A, Penson P, et al. The effects of cinnamon supplementation on blood lipid concentrations: a systematic review and meta-analysis. J Clin Lipidol. 2017;11:1393–406.PubMedCrossRef
75.
Cicero AFG, Fogacci F, Zambon A. Red yeast rice for hypercholesterolemia: JACC focus seminar. J Am Coll Cardiol. 2021;77:620–8.PubMedCrossRef
76.
Gerards MC, Terlou RJ, Yu H, Koks CHW, Gerdes VEA. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain – A systematic review and meta-analysis. Atherosclerosis. 2015;240:415–23.PubMedCrossRef
77.
Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, et al. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689–93.PubMedCrossRef
78.
Fogacci F, Banach M, Mikhailidis DP, et al. Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2019;143:1–16.PubMedCrossRef
79.
Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: Buyer beware! Arch Intern Med. 2010;170:1722–7.PubMedCrossRef
80.
Gordon RY, Becker DJ. The role of red yeast rice for the physician. Curr Atheroscler Rep. 2011;13:73–80.PubMedCrossRef
81.
Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin: IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys. 1991;290:355–61.PubMedCrossRef
82.
Banach M, Patti AM, Giglio RV, et al. The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol. 2018;72:96–118.PubMedCrossRef
83.
Becker DJ, Gordon RY, Halbert SC, French B, Morris PB, Rader DJ. Red yeast rice for dyslipidemia in statin-intolerant patients. Ann Intern Med. 2009;150:830–9.PubMedCrossRef
84.
Halbert SC, French B, Gordon RY, Farrar JT, Schmitz K, Morris PB, et al. Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105:198–204.PubMedCrossRef
85.
Yeh GY, Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol. 2006;98:673–80.PubMedCrossRef
86.
Singh DK, Porter TD. Inhibition of sterol 4α-methyl oxidase is the principal mechanism by which garlic decreases cholesterol synthesis. J Nutr. 2006;136:759S-764S.PubMedCrossRef
87.
Ried K, Toben C, Fakler P. Effect of garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013;71:282–99.PubMedCrossRef
88.
•• Laffin LJ, Bruemmer D, Garcia M, et al. Comparative Effects of Low-Dose Rosuvastatin, Placebo, and Dietary Supplements on Lipids and Inflammatory Biomarkers. J Am Coll Cardiol. 2023;81:1–12. Recent randomized controlled trial comparing the safety and efficacy of six common dietary supplements used for "cholesterol health" against statins and placebo.PubMedCrossRef
Metadaten
Titel
Supplements for Lipid Lowering: What Does the Evidence Show?
verfasst von
Saeid Mirzai
Luke J. Laffin
Publikationsdatum
10.06.2023
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 8/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01903-9

Weitere Artikel der Ausgabe 8/2023

Current Cardiology Reports 8/2023 Zur Ausgabe

Diversity and Health Equity in Cardiology (AE Johnson, Section Editor)

Incidence and Prevalence of Atrial Fibrillation in Latinos: What’s New Since the Study in Latinos (SOL)?

Cardio-Oncology (LA Baldassarre, Section Editor)

Approaches to Prevent and Manage Cardiovascular Disease in Patients Receiving Therapy for Prostate Cancer

Public Health Policy (SS Virani and D Mahtta, Section Editors)

Broadening Heart Failure Care Beyond Cardiology: Challenges and Successes Within the Landscape of Multidisciplinary Heart Failure Care

Cardio-Oncology (LA Baldassarre, Section Editor)

Cardio-oncology: Shared Genetic, Metabolic, and Pharmacologic Mechanism

Heart Failure (HJ Eisen, Section Editor)

COVID-19 and Acute Cardiac Injury: Clinical Manifestations, Biomarkers, Mechanisms, Diagnosis, and Treatment

Myocardial Disease (A Abbate and M Merlo, Section Editors)

Clinical Features of Takotsubo Syndrome and Its Differential Diagnostic Criteria in Clinical Nursing Practice: A Review of the Literature

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen